Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds

NCT ID: NCT00640822

Last Updated: 2025-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 782 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2009-07-31

Brief Summary

There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares

Conditions

Psoriasis Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Calcipotriol plus Hydrocortisone ointment

Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks

Group Type: EXPERIMENTAL

Calcipotriol plus hydrocortisone ointment

Intervention Type: DRUG

Once daily application for up to 8 weeks

Tacalcitol

Tacalcitol once daily for up to 8 weeks

Group Type: ACTIVE_COMPARATOR

Tacalcitol Ointment

Intervention Type: DRUG

Once daily application for up to 8 weeks

Calcipotriol plus Hydrocortisone ointment vehicle

Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks

Group Type: PLACEBO_COMPARATOR

Calcipotriol plus hydrocortisone ointment vehicle

Intervention Type: DRUG

Once daily application for up to 8 weeks

Interventions

Calcipotriol plus hydrocortisone ointment vehicle

Once daily application for up to 8 weeks

Intervention Type: DRUG

Tacalcitol Ointment

Once daily application for up to 8 weeks

Intervention Type: DRUG

Calcipotriol plus hydrocortisone ointment

Once daily application for up to 8 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of psoriasis vulgaris involving the face
• Clinical signs of psoriasis vulgaris on the trunk and/or the limbs, or earlier diagnosed with psoriasis vulgaris on the trunk and/or the limbs
• An extent of psoriatic involvement of the face of at least 10 cm2 (the sum of all facial lesions)
• Treatment areas (the face and the intertriginous areas) amenable to topical treatment with a maximum of 10 g of ointment per day
• Disease severity graded as mild, moderate, severe or very severe according to the investigator's global assessment of disease severity of the face

Exclusion Criteria

• Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation
• Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (e.g., alefacept, efalizumab, etanercept, infliximab, adalimumab) within 3 months prior to randomisation
• PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation
• UVB therapy within the 2-week period prior to randomisation
• Topical treatment of the face and the intertriginous areas within the 2-week period prior to randomisation (use of emollients is allowed on treatment areas during this 2-week period, but not during the study)
• Topical treatment with very potent WHO group IV corticosteroids within the 2-week period prior to randomisation
• Initiation of or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during the study
• Systemic treatment with vitamin D preparations above 500 IU per day
• Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
• Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
• Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas
• Planned exposure to sun, UVA or UVB that may affect the psoriasis vulgaris during the study
• Known or suspected severe renal insufficiency or severe hepatic disorders
• Known or suspected disorders of calcium metabolism associated with hypercalcemia

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LEO Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Colin Fleming, MD

Role: PRINCIPAL_INVESTIGATOR

Ninewells Hospital & Medical School

Locations

Probity Medical Research

Waterloo, Ontario, Canada

Hôpital de l'Archet

Nice, , France

Ninewells Hospital & Medical School

Dundee, , United Kingdom

Countries

Canada; France; United Kingdom

Other Identifiers

LEO 80190-O22

Identifier Type: -

Identifier Source: org_study_id